Three recalls in a row from the same pharmaceutical company is the kind of thing that tends to make patients a little nervous, and frankly, who could blame them.
Crescent Pharma has issued its third recall of a blood pressure medication, adding to growing concerns about quality control at the UK-based manufacturer. The latest recall affects amlodipine tablets, a calcium channel blocker commonly prescribed to treat hypertension and angina, used by hundreds of thousands of people across Britain.
The Medicines and Healthcare products Regulatory Agency (MHRA) confirmed the recall, advising patients who’ve been prescribed the affected batches not to stop taking their medication without first speaking to their GP or pharmacist. That’s crucial advice; suddenly stopping blood pressure treatment can carry its own serious risks.
The specific concern centres on the tablets potentially not meeting required quality standards, though the MHRA hasn’t indicated there’s an immediate safety risk to patients who’ve already taken them. Still, a third recall does raise questions about manufacturing processes that are difficult to simply brush aside.
“Patients should not stop taking their medication without consulting a healthcare professional first,” an MHRA spokesperson advised, echoing guidance that pharmacists up and down the country have been repeating to concerned customers this week.
Crescent Pharma, which supplies a range of generic medicines to the NHS, has faced increasing scrutiny following the previous two recalls. The company hasn’t yet issued a detailed public statement explaining what’s gone wrong or what corrective steps are being taken to prevent a fourth.
For anyone taking amlodipine, the NHS has confirmed that alternative supplies from other manufacturers are available, and most pharmacies should be able to swap out affected stock without any significant disruption to treatment. It’s worth contacting your pharmacy directly if you’re unsure whether your prescription is affected.
High blood pressure affects roughly 14 million adults in the UK, making reliable access to these medications genuinely critical for a large slice of the population. The bigger question now is whether regulators will step up their oversight of Crescent Pharma’s manufacturing sites before any further recalls become necessary.
